Trade name: Jyocef S
Strength: Ceftriaxone 1 g, sulbactam 500 mg.
Active ingredient: Ceftriaxone, sulbactam
Category: Ceftriaxone is a 'third generation' cephalosporin antibiotic. Sulbactam is a ß-lactamase inhibitor.
Pregnancy category: Ceftriaxone belongs to Australia therapeutic goods administration (TGA) pregnancy category: B1 AND US FDA pregnancy category: B (No risk in non-human studies). Sulbactam belongs to US FDA pregnancy category: B (No risk in non-human studies).
Uses: Jyocef S 1000 mg injection is used to treat a wide variety of bacterial infections such as bacteremia, joint Infection, skin Infection, osteomyelitis (infection of the bone), pneumonia (lung infection), septicemia, urinary tract infection, bronchitis (inflammation of the lining of bronchial tubes), Meningitis (Inflammation of brain and spinal cord membranes), pelvic inflammatory disease, Chancroid, Conjunctivitis also called as pinkeye (inflammation of the conjunctiva), endocarditis (inflammation of the inside lining of the heart chambers and heart valves), epididymitis (Inflammation of the tube at the back of the testicle that stores and carries sperm) - Sexually Transmitted, Gonococcal Infection - Disseminated, Lyme Disease (Arthritis, Carditis, Neurologic), Meningococcal Meningitis Prophylaxis, neurosyphilis (syphilis that involves the central nervous system.), Proctitis (inflammation of the rectum and anus), STD Prophylaxis, early syphilis.
How to use: Jyocef S 1000 mg injection is given by health care provider at doctors office. It is given as a drip (intravenous infusion) or as an injection directly into a vein (intravenous) or into a muscle (intramuscular). Do not drive while taking this medication as it cause dizziness.
Side Effects: Mild diarrhea; mild pain, swelling, weakness, shortness of breath when exercising, redness at the injection site, nausea and vomiting.
Dosage: Usual adult dose: 1 to 2 g by intravenous or intra muscular once a day.
Written by: : healthplus24.com team
Date last updated: September 16th, 2016
Subscribe to our email newsletter.